Glycol-splitting as a device for modulating inhibition of growth factors and heparanase by heparin and heparin derivatives

Chemistry and Biology of Heparin and Heparan Sulfate

Volumn , Issue , 2005, Pages 461-481

  Naggi, Annamaria ^a  

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748688639     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008044859-6/50017-4     Document Type: Chapter

References (65)

1. Casu B Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 1985, 43:51-132.
2. Conrad HE Heparin Binding Proteins 1998, Academic Press, San Diego, CA.
3. Capila I, Linhardt RJ Heparin-protein interactions. Angew Chem Int 2002, 41:390-412.
4. Linhardt RJ Heparin: Structure and activity. J Med Chem 2003, 46:2551-2564.
5. Choay J, Lormeau JC, Petitou M, Fareed P, Sinay P Low molecular weight oligosaccharides active in plasma against factor Xa. II New structural elements and antithrombotic activity. Ann Pharma Fr 1981, 39:267-272.
6. 13C nuclear-magnetic-resonance studies. Biochem J 1981, 197:599-609.
7. Hircovini M, Guerrini M, Bisio A, Torri G, Petitou M, Casu B Conformation of heparin pentasaccharide bound to Antithrombin III. Biochem J 2001, 359:265-272.
8. Conrad HE, Guo Y Structural analysis of periodate-oxidized heparin. Advances in Experimental Medicine and Biology 1992, vol. 313:31-36. Plenum Press, New York. D.A. Lane, I. Björk, U. Lindahl (Eds.).
9. Foster AB, Webber JM The structure of heparin. Biochem J 1964, 91:1P.
10. Casu B, Diamantini G, Fedeli G, Mantovani M, Oreste P, Pescador R, Porta R, Prino G, Torri G, Zoppetti G Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. Arzneim Forsch/Drug Res 1986, 36(4):637-642.
11. Ferro DR, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V, Perly B, Sinay P, Petitou M, Choay J Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res 1990, 19:157-167.
12. Casu B Structure, shape and function of glycosaminoglycans. New Trends in Haemostasis: Coagulation Proteins, Endothelium, and Tissue Factors 1990, 2-11. Springer-Verlag, Heidelberg. J. Harenberg, D.L. Heene, G. Stehle, G. Schettler (Eds.).
13. Cross MJ, Claesson-Welsh L FGF and VEGF function in angiogenesis: Signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacologic Sci 2001, 22:201-207.
14. Vlodavskyl I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, Peretz T, Friedmann Y Mammalian heparanase: Involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2002, 12(2):121-129.
15. Casu B, Guerrini M, Naggi A, Perez M, Torri G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry 2002, 41:10519-10528.
16. Pellegrini L Role of heparan sulfate in fibroblast growth factor signaling: A structural view. Curr Opin Struct Biol 2001, 11:629-634.
17. Perlin AS Glycol-cleavage oxidation. The Carbohydrates Chemistry and Biochemistry 1980, IB:1167-1207. Academic Press, New York. W. Pigman, D. Horton, J. Wander (Eds.).
18. Timms ID, Tomaszewski JE, Shlansky-Goldberg RD Effect of nonanticoagulant heparin (Astenose) on restenosis after balloon angioplasty in the atherosclerotic rabbit. J Vasc Intervent Radiol 1995, 6:365-378.
19. Fransson L, Malmström A, Sjöberg I, Huckeberry TN Periodate oxidation and alkaline degradation of heparin-related glycans. Carbohydr Res 1980, 80:131-145.
20. Sache E, Maillard M, Malazzi P, Bertrand H Partially N-desulfated heparin as a non-anticoagulant heparin: some physico-chemical and biological properties. Thromb Res 1989, 55:247-258.
21. a and conformation of hexuronic acids in polyuronides and mucopolysaccharides. Biochimica Biophysica Acta 1968, 170(2):471-473.
22. Conrad HE, Guo G Structural analysis of periodate-oxidized heparin. Heparin and Related Polysaccharides 1992, 31-36. Plenum Press, New York. D.A. Lane (Ed.).
23. Fransson L, Lewis W Relationship between anticoagulant activity of heparin and susceptibility to periodate oxidation. FEBS Lett 1979, 97:119-123.
24. Thunberg L, Bäckström G, Grundberg H, Riesenfeld J, Lindahl U The molecular size of the antithrombin-binding sequence in heparin. FEBS Lett 1980, 117:203-206.
25. 13C-NMR spectroscopy for characterization of heparin preparations. Semin Thromb Hemost 2001, 27:473-482.
26. Hricovini M, Guerrini M, Bisio A, Torri G, Petitou M, Casu B Conformation of heparin pentasaccharide bound to Antithrombin III. Biochem J 2001, 359:265-272.
27. Islam T, Butler M, Sikkander SA, Toida T, Linhardt RJ Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. Carbohydr Res 2002, 337:2239-2243.
28. Linker A, Hovingh P Enzymatic degradation of heparin as a tool for structural analysis. Heparin: Structure, Cellular Functions, and Clinical Application 1979, 3-24. Academic Press, New York. N.M. McDuffie (Ed.).
29. Nader H, Dietrich C, Oreste P, Dell'Eva M Substrate specificity of heparinase and heparitinases. Cleavage of chemically-modified heparins and heparin sulfate. Biomedical and Biotechnological Advances in Industrial Polysaccharides 1989, 89-100. Gordon and Breach, New York. V. Crescenzi, I. Dea, S. Paoletti, S. Stivala (Eds.).
30. Kovensky J, Cirelli AF Chemical modification of glycosaminoglycans. Sulfation of heparansulfate derivatives obtained by periodate oxidation/borohydride reduction. Carbohydr Polymers 1996, 31:211-214.
31. Jaseja M, Rej RN, Sauriol F, Perlin AS Novel regio- and stereoselective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence. Can J Chem 1989, 67:1449-1456.
32. Rej RN, Perlin AS Base-catalyzed conversion of the oL-L-iduronic acid 2-sulfate unit into a unit of oL-L-galacturonic acid, and related reactions. Carbohydr Res 1990, 200:427-447.
33. Piani S, Casu B, Marchi EG, Torri G, Ungarelli F Alkali induced optical rotation changes in heparins and heparin sulfates, and their relation to iduronic acid-containing sequences. J Carbohydr Chem 1995, 12:507-521.
34. Casu B, Guerrini M, Guglieri S, Naggi A, Perez M, Torri G, Cassinelli G, Ribatti D, Carminati P, Giannini G, Penco S, Pisano C, Belleri M, Rusnati M, Presta M Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 2004, 47:838-848.
35. Pellegrini L Role of heparan sulfate in fibroblast growth factor signaling: a structural view. Curr Opin Struct Biol 2001, 11:629-634.
36. Guimond S, Maccarana M, Olvin BB, Lindahl U, Rapraeger AC Activating and inhibitory heparin sequences for FGF-2 (basic FGF). J Biol Chem 1993, 268:23906-23914.
37. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, Waksman G FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 1995, 268:432-436.
38. Lundin L, Larsson H, Krueger J, Kanda S, Lindahl U, Salvimirta M, Claesson-Welsh L Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogeneity and angiogenesis. J Biol Chem 2000, 275:24653-24660.
39. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 1992, 12:240-247.
40. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, Vlodavsky I Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol-splitting. J Biol Chem 2005, 280:12103-12113.
41. Ferrara N, Gerberet HP, Le Couter J The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
42. Gitay-Goren SS, Vlodavsky I, Neufed G The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992, 267:6093-6098.
43. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lemischka IR, Neufeld G Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 1994, 69:12456-12461.
44. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ, Neufeld G VEGG121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparin sulphate for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 1995, 270:11322-11326.
45. Margolin K Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep 2002, 4:20-28.
46. Pisano C, Aulicino C, Vesci L, Casu B, Naggi A, Torri G, Ribatti D, Belleri M, Rusnati M, Presta M Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005, 15(2):1C-6C.
47. Vlodavsky I, Friedmann Y Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001, 108:341-347.
48. Parish CR, Freeman C, Hulett MD Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 2001, 1471:M99-M108.
49. Dempsey LA, Brunn GT, Platt JL Heparanase, a potential regulator of cell-matrix interactions. Trends Biol Sci 2000, 25:349-351.
50. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lide O, Naparstek Y, Cohen IR, Fuks Z Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992, 12:112-127.
51. Ribatti D, Gualandris A, Bastaki M, Vacca A, Roncali L, Presta M New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997, 34:445-463.
52. Ribatti D, Bertossi M, Nico B, Vacca A, Ria R, Riva A, Roncali L, Presta M Role of basic fibroblast growth factor in the formation of the capillary plexus in the chick embryo chorioallantoic membrane. An in situ hybridization, immunohistochemical and ultrastructural study. J Submicrosc Cytol Pathol 1998, 30:127-136.
53. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N, Vlodavsky I, Abramovitch R Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005, 19:211-222.
54. Vlodavsky I, Zcharia E, Goldshmidt O, Eshel R, Katz BZ, Minucci S, Kovalchuk O, Penco S, Pisano C, Naggi A, Casu B Involvement of heparanase in tumor progression and normal differentiation. Pathophysiol Haemost Thromb 2003, 33:59-61.
55. Lapierre F, Holme K, Lam L, Tressler RJ, Storm N, Wee J Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996, 6:355-366.
56. Yoshitomi Y, Nakanishi H, Kusano Y, Munesue S, Oguri K, Tatematsu M, Yamashina I, Okayama M Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemical modified heparin with reduced anticoagulant activity. Cancer Lett 2004, 207:165-174.
57. Lipari G, Szabo A Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J Am Chem Soc 1982, 104:4546-4559.
58. Guerrini M, Hricovini M, Naggi A, Torri G, Guglieri S, Casu B Influence of molecular motion on activation of growth factors by heparin derivatives. Seventh European NMR Large Scale Facilities User Meeting 2003, 43.
59. Korramian BA Small-angle X-ray scattering of reduced oxyheparins. Industrial Polysaccharides 1987, 339-347. Gordon and Breach, New York. S.S. Stivala, V. Crescenzi, I.C.M. Dea (Eds.).
60. Mulloy B, Forster MJ, Jones C, Davies DB NMR and molecular-modelling studies of the solution conformation of heparin. Biochem J 1993, 293:849-858.
61. Still WC, Tempczyk A, Hawlely R, Hendrickson TA General treatment of solvation for molecular mechanics. J Am Chem Soc 1990, 112:6127-6129.
62. Venkataraman G, Shriver Z, Davis JC, Sasisekharan R Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans. Acad Sci USA 1999, 96:1892-1897.
63. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC Heparin structure and interactions with basic fibroblast growth factor. Science 1996, 271:1116-1120.
64. Okada Y, Yamada S, Toyoshima M, Dong J, Nakajima M, Sugahara K Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 2002, 277:42488-42495.
65. Ono K, Hattori H, Takeshita S, Kurita A, Ishihara M Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 1999, 9:705-711.